Adlai Nortye, a Hangzhou biopharma, closed a $50 million Series B round led by Yuanming Capital. Adlai Nortye describes itself as a science-led discovery and in-licensing biopharma focused on new drugs for cancer and metabolic diseases. So far, it has three announced molecules of its own, currently in pre-clinical development, and it has in-licensed rights to two clinical-stage immunoncology products — one from Canada’s Oncolytics Biotech and the other from Eisai of Japan.
Source: China Biotoday
